Rebecca Gonzalez, PharmD, BCOP, Moffitt Cancer Center, Tampa, FL, gives an overview of the latest developments in strategies for graft-versus-host disease (GvHD) prevention, discussing the results of the BTM CTN 1703 (NCT03959241) study that showed the superiority of post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil (TAC/MMF/PTCy) over tacrolimus/methotrexate (TAC/MTX), and discussing the efficacy and toxicity of abatacept. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.